Literature DB >> 26989067

Quality Control of Insulins and Biosimilar Insulins: What Do We Know?

Alan W Carter1, Lutz Heinemann2, David C Klonoff.   

Abstract

Keywords:  biosimilar insulin; insulin; quality; therapy

Mesh：

Substances：

Year:  2016        PMID： 26989067      PMCID： PMC4928234          DOI： 10.1177/1932296816638923

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


× No keyword cloud information.
  3 in total

Review 1.  The emergence of biosimilar insulin preparations--a cause for concern?

Authors:  David R Owens; Wolfgang Landgraf; Andrea Schmidt; Reinhard G Bretzel; Martin K Kuhlmann
Journal:  Diabetes Technol Ther       Date:  2012-10-09       Impact factor: 6.118

2.  In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?

Authors:  Alan W Carter
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

3.  Quality of original and biosimilar epoetin products.

Authors:  Vera Brinks; Andrea Hawe; Abdul H H Basmeleh; Liliana Joachin-Rodriguez; Rob Haselberg; Govert W Somsen; Wim Jiskoot; Huub Schellekens
Journal:  Pharm Res       Date:  2010-10-01       Impact factor: 4.200
  3 in total
  2 in total

1.  Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain.

Authors:  Alan W Carter; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2017-12-21

2.  If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?).

Authors:  Alan W Carter; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.